Loading...
•
Dec 31, 2020
Allogene Q4 2020 Earnings Report
Allogene experienced growth driven by the advancement of AlloCAR T candidates and the establishment of Allogene as a leader in cell therapy.
Key Takeaways
Allogene Therapeutics reported fourth quarter and full year 2020 financial results, highlighting the progress of AlloCAR T candidates, IND submissions, and the completion of Cell Forge 1. The company ended the year with $1.0 billion in cash, cash equivalents, and investments.
Presented initial Phase 1 UNIVERSAL Trial data on ALLO-715 at ASH, providing first proof-of-concept for an AlloCAR T therapy in relapsed/refractory multiple myeloma.
Updated ALLO-501 and initial ALLO-501A AlloCAR T data in Non-Hodgkin Lymphoma (NHL) planned for Q2 2021.
ALLO-501A Granted FDA Fast Track Designation for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL), a Type of NHL.
Ended 2020 with $1.0 Billion in Cash, Cash Equivalents and Investments.
Forward Guidance
Allogene expects full year GAAP Operating Expenses to be between $300 million and $330 million including estimated non-cash stock-based compensation expense of $80 million to $90 million and excluding any impact from potential new business development activities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...